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Abstract Colistin-susceptible isolates of Acinetobacter
baumannii often contain subpopulations that are resistant to
colistin. Monotherapy with colistin can lead to selective growth
of these subpopulations and emergence of colistin-resistant
strains. Our objectives were to explore the susceptibility pattern
of colistin-resistant subpopulations and investigate if combin-
ing colistinwith a second antibiotic could prevent their selective
growth. Four colistin-susceptible clinical isolates of
A. baumannii and one reference isolate were used. The mutant
prevention concentration (MPC) of colistin, i.e. the concentra-
tion required to block growth of all single-step-mutant subpop-
ulations, was determined by plating an inoculum of 109 CFUon
Mueller Hinton agar (MHA)-plates containing 2-fold dilutions
of colistin (0.125–128 mg/L). Susceptibility testing of colistin-
resistant subpopulations, obtained in the MPC assay, was per-
formed with Etest. The MPC of colistin, in combination with
rifampicin, was determined by plating an inoculum of 109 CFU
onMHA-plates containing colistin (0.125–128mg/L) and fixed
concentrations of rifampicin (1.1 mg/L or 4.4 mg/L). The
colistin-resistant subpopulations demonstrated increased sus-
ceptibility to a number of agents compared to their main popu-
lations. These subpopulations were even susceptible to agents
that normally are inactive against gram-negative bacteria and all
had rifampicin MICs of < 0.002 mg/L. The combination of co-
listin and rifampicin completely inhibited the growth of all
colistin-resistant subpopulations and significantly lowered the
MPC of colistin for A. baumannii. Combining colistin with
rifampicin could be a way to prevent selective growth of
colistin-resistant subpopulations of A. baumannii and possibly
the emergence of colistin-resistant strains.
Introduction
Acinetobacter baumannii has emerged as an important cause
of nosocomial infections. Its clinical significance is primarily
related to its remarkable ability to upregulate and acquire re-
sistant determinants, making it notoriously difficult to treat
[1]. Surveillance studies now show that >80 % of invasive
isolates of A. baumannii are carbapenem resistant in some
European countries [2].
Colistin is an antibiotic with bactericidal effect against
gram-negative bacteria. It is often used as a last resort treat-
ment for multi drug-resistant (MDR) gram-negative bacteria,
including carbapenem-resistant A. baumannii [3].
Unfortunately, colistin-resistant strains of A. baumannii have
emerged [4, 5]. As a consequence we now face the risk of
infections caused by A. baumannii that cannot be treated with
antimicrobials.
Heteroresistance to colistin due to resistant subpopulations
is a well-described phenomenon among A. baumannii [4].
Colistin-resistant strains can develop if the colistin concentra-
tion is sufficient to prevent growth of the susceptible main
population but not the resistant subpopulations [6]. The con-
centration required to prevent such selective growth is called
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defined as the concentration required to block growth of all
single-step-mutant subpopulations [7, 8].
The MPC of colistin in vitro for A. baumannii has been
shown to be so high that it cannot be exceeded in vivo.
These results suggest that monotherapy with colistin will
inevitably lead to selective growth of colistin-resistant
subpopu l a t i on s . The MPC of co l i s t i n aga ins t
A. baumannii was lowered when colistin was combined
with levofloxacin or tobramycin. It was however still well
beyond clinically achievable concentrations [9, 10]. The
results from one study implicate that other agents, for
example, rifampicin and meropenem, may be more effec-
tive in lowering the MPC [11].
Our first objective was to explore the susceptibility pattern of
colistin-resistant subpopulations of A. baumannii. Our second
objective was to investigate if we could prevent their selective
growth by combining colistin with a second antibiotic that the
colistin-resistant subpopulations were susceptible to.
Material and methods
Characterization of bacterial isolates Four clinical isolates
(AB1-AB4) of A. baumannii isolated from four different patients
during 2013 at the Department of Clinical Microbiology,
Linköping University Hospital (Linköping, Sweden) were in-
cluded. Species identification was done with MaldiTof (Bruker
Daltonics Scandinavia AB, Solna Sweden). Pulse-field gel elec-
trophoresis (PFGE) and determination of the resistance genes
present in AB1-AB4 were performed at the Public Health
Agency of Sweden (Solna, Sweden). According to PFGE the
four isolates represented four different clones. The following
carbapenemase genes were identified: OXA 23 (AB1-AB3),
OXA 51 (AB1-AB4), OXA 58 (AB4) and NDM (AB1). All
clinical isolates were defined as MDR according to proposed
nomenclature [12], but classified as susceptible to colistin (S ≤
2mg/L) [13]. A. baumanniiCCUG19096 (AB5), Pseudomonas
aeruginosa ATCC 27853 and Escherichia coli ATCC 25922,
obtained from the Culture Collection, Göteborg University,
Sweden, were used as type strains.
MIC of colistin determined with Etest, broth dilution and
agar dilution Colistin MIC was determined for isolates AB1-
5 with Etest (bioMérieux, Marcy l’Etoile, France), broth dilu-
tion and agar dilution. Colistin Etest was applied on Mueller-
Hinton Agar (MHA) (Becton Dickinson, Franklin Lakes, NJ,
USA) inoculated with a bacterial suspension of 0.5McFarland
in 0.85 % NaCl and was read after 24 h incubation at 36 °C.
Broth dilution MIC of colistin sulphate (Sigma-Aldrich corp.,
St Louis, MO, USA) was determined with 2-fold dilutions
(0.016–256 mg/L) in glass tubes containing 1 mL Mueller-
Hinton Broth (MHB) (Becton Dickinson), with an inoculum
of approximately 1 × 105 CFU/mL. Broth dilution MIC was
defined as the lowest concentration inhibiting visible growth
after 24 h of incubation at 36 °C. Agar dilution MIC was
determined with MHA (Becton Dickinson) plates with 2-
fold dilutions of colistin sulphate (Sigma Aldrich), ranging
from 0.08 to 2.0 mg/L. A bacterial suspension of approximate-
ly 105 CFU/mL, determined by viable count, was prepared by
dilution with NaCl 0.85 % of an overnight culture of 3 mL
MHB (Becton Dickinson). Plates were spot inoculated, with
two spots and 104 CFU in each spot. The plates were incubat-
ed overnight at 36 °C. Agar-MIC was defined as the lowest
concentration that inhibited visible growth. All tests were per-
formed in duplicates to ensure reproducibility.
MPC of colistin determined with agar dilution The MPC
was determined with a method described by Cai et al. [9], but
with modifications. Isolates AB1-5 were grown overnight on
Columbia agar (Acumedia, Lansing, MI, USA) with 5 % de-
fibrinated horse blood (Håtuna, Uppsala, Sweden) at 36 °C.
Glass tubes containing 2 mL MHB (Becton Dickinson) were
inoculated with bacteria from the Columbia agar and incubat-
ed overnight at 36 °C with shaking, reaching a bacterial con-
centration of 109 CFU/mL, determined by viable count.
Aliquots of 1 mL were plated on MHA-plates (Becton
Dickinson) containing colistin sulphate (Sigma Aldrich) in
2-fold dilutions (0.125–128 mg/L). The MPC was defined as
the lowest concentration of colistin that inhibited all visible
growth of 109 CFU after 48 h of incubation [7]. Colonies were
isolated from the plates with the highest and the second
highest colistin concentration with growth of bacteria.
MaldiTof (Bruker) was used to determine that the colonies
were A. baumannii, and Etest (bioMérieux) was used to de-
termine their susceptibility to colistin. The tests were per-
formed in duplicates to ensure reproducibility.
MIC of the main populations (AB1-5) and the colistin-
resistant subpopulations determined with Etest The main
populations of the isolates AB1-5 and the colistin-resistant
subpopulations isolated from the colistin plates in the MPC
assay were studied further. The MIC of colistin, vancomycin,
rifampicin, meropenem, linezolid, ampicillin/sulbactam, tige-
cycline, ciprofloxacin and tobramycin was determined with
Etest (bioMérieux) on MHA-plates (Becton Dickinson) inoc-
ulated with a bacterial suspension adjusted to 0.5 McFarland
in 0.85 % NaCl. The MIC was read after 24 h of incubation at
36 °C for vancomycin and colistin and after 18 h for the
remaining agents.
MPC of colistin in combination with rifampicin deter-
mined with agar dilution Bacterial suspensions with a con-
centration of 109 CFU/mL were generated for isolate AB1-
AB5 as described above in the method for the MPC of colistin
determined with agar dilution. Aliquots of 1 ml were plated on
MHA-plates (Becton Dickinson) containing colistin sulphate
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(Sigma Aldrich) 0.125–128 mg/L (using 2-fold dilutions) in
combination with fixed concentrations of rifampicin (Sigma
Aldrich) 1.1 or 4.4 mg/L. We choose concentrations of rifam-
picin that we considered clinically relevant. Free unbound
concentration of 1.1 mg/L can readily be achieved with per
oral administration of 600 mg rifampicin and 4.4 mg/L with
900 mg [14, 15]. The tests were performed in duplicates to
ensure reproducibility. The MPC was defined as the lowest
concentration of colistin that inhibited all visible growth of an
inoculum of 109 CFU after 48 h of incubation at 36 °C [7].
Colonies were isolated from the plates with the highest and the
second highest colistin concentration with growth of bacteria.
MaldiTof (Bruker) was used to determine that the colonies
were A. baumannii and Etest (bioMérieux) to determine their
susceptibility to colistin and rifampicin.
Results
Colistin MIC The MIC of colistin for the main population
determined with Etest, agar dilution and broth dilution were
0.125, 0.25–0.5 and 0.50–1 mg/L, respectively (Table 1).
MPC of colistin alone The MPC was 64 mg/L for all isolates
except AB3 that displayed an MPC-value of 16–32 mg/L
(Table 2). Colistin-resistant subpopulations were recovered
from MHA-plates containing 16–32 mg/L colistin for all test-
ed isolates in the frequency of 1 of 107–109, except for AB3
from which no colistin-resistant subpopulations were recov-
ered. Subpopulations displaying colistin-dependent growth
were also recovered from colistin-containing plates for iso-
lates AB1 and AB2 (Fig. 1a). Colistin-susceptible cells were
detected on plates containing colistin 8–32 mg/L in all iso-
lates. They were most often found co-existing with colistin-
resistant subpopulations, but not always.
Antibiograms for main populations and colistin-resistant
subpopulations MIC values with Etest were determined for
the main populations and the colistin-resistant subpopulations
(Table 3). The main population of four isolates (AB1-4) were
MDR [12] with high MIC values for all antimicrobial agents
tested, except for colistin. The main population of one isolate
displayed high-level resistance to rifampicin >32 mg/L (AB3)
while the other isolates' main populations had MIC values of
4–8 mg/L. The colistin-resistant subpopulations clearly
displayed increased susceptibility to rifampicin, vancomycin
and meropenem compared to the main populations. The ri-
fampicin MICs were much lower (<0.002 mg/L) for all
colistin-resistant subpopulations compared to the main popu-
lations (Fig. 1b).
MPC of colistin in combination with rifampicin We chose
to combine colistin with rifampicin because of the results in
the antibiogram study described above. The MPC-values of
colistin when combined with rifampicin at fixed concentra-
tions of 1.1 mg/L or 4.4 mg/L are reported in Table 2. The
MPCwas lowered from 64mg/L to 8–16mg/L for the isolates
AB1, AB2, AB4 and AB5 when colistin was combined with
rifampicin 1.1 mg/L or 4.4 mg/L. The MPC was not lowered
for the AB3 isolate. No difference regarding the MPC could
be seen when comparing plates containing rifampicin 1.1 mg/
L and rifampicin 4.4 mg/L. Interestingly, no colistin-resistant
subpopulations were detected on any of the MHA plates con-
taining both colistin and rifampicin 1.1 mg/L or 4.4 mg/L. We
Table 1 MIC determination of
colistin with Etest, agar and broth
dilution assay
Isolate Etest MIC (mg/L) Agar dilution MIC (mg/L) Broth dilution MIC (mg/L)
AB1 0.125 0.5 1
AB2 0.125 0.5 1
AB3 0.125 0.25 1
AB4 0.125 0.25 0.5
AB5 0.125 0.5 1
Table 2 Mutant prevention
concentration (MPC) of colistin
alone and in combination with ri-
fampicin 1.1 mg/L or 4.4 mg/L
Isolate MPC (mg/L)
Colistin alone Colistin + 1.1 mg/L rifampicin Colistin + 4.4 mg/L rifampicin
AB1 64 8–16 8–16
AB2 64 16 8–16
AB3 16–32 16–32 32
AB4 64 8 8
AB5 64 8–16 8–16
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detected colistin-susceptible cells with high-level resistance
against rifampicin on MHA-plates containing both colistin
and rifampicin in all isolates. No difference could be seen
when comparing plates containing rifampicin 1.1 mg/L and
4.4 mg/L.
Discussion
Colistin-resistant strains of A. baumannii can develop during
colistin therapy if colistin-resistant subpopulations grow selec-
tively [16–19]. We hypothesized that such growth could be
prevented if colistin was combined with an agent effective
against these subpopulations. The colistin-resistant subpopula-
tions were extremely susceptible to rifampicin (MIC <
0.002 mg/L) and the combination of colistin and rifampicin
completely inhibited the growth of all colistin-resistant subpop-
ulations and significantly lowered the MPC of colistin.
The colistin-resistant subpopulations demonstrated in-
creased susceptibility to a number of agents compared to their
main population. They were even susceptible to rifampicin
and vancomycin, agents that normally are inactive against
gram-negative bacteria. These findings are likely due to
increased outer membrane permeability, allowing greater ac-
cess to target sites for these agents. One study reported similar
results [11]. Meropenem and especially rifampicin demon-
strated the greatest potential to prevent selective growth, with
MICs for the colistin-resistant subpopulations of 0.016–
0.5 mg/L and < 0.002 mg/L, respectively. Rifampicin has the
advantage of not being nephrotoxic, but has the disadvantages
of possible hepatotoxicity and drug interactions [20]. The
broad spectrum of meropenem could be of benefit since many
patients infectedwithA. baumannii are co-infected [20], while
disadvantages are possible nephrotoxicity when it is combined
with colistin [21] and the risk of an increase in carbapenem
resistance if carbapenem consumption is increased [22].
We chose to combine colistin with rifampicin because of
the colistin-resistant subpopulations extreme susceptibility to
this agent. To our knowledge no previous study has investi-
gated the effect on the MPC of colistin for A. baumanniiwhen
rifampicin is added. In our study the MPC of colistin was
lowered ≥ 2 dilution steps in all heteroresistant isolates when
rifampicin was added in clinically achievable concentrations.
No colistin-resistant subpopulations were recovered from any
MHA-plates containing both colistin and rifampicin. These
results show that rifampicin can prevent selective growth of
colistin-resistant subpopulations in vitro. Our results are sup-
ported by other in vitro studies [19, 23]. Most in vitro studies
have shown 100 % synergy for the colistin-rifampicin combi-
nation against MDR A. baumannii with low to intermediate
rifampicin resistance (MIC ≤ 16 mg/L) [24, 25]. It is possible
that a synergistic effect contributed to the lowered MPC seen
in our heteroresistant isolates.
Evidence that rifampicin prevents the development of
colistin-resistance in vivo is still lacking, although a colistin-
resistant strain of A. baumannii has successfully been treated
with rifampicin [19]. We have found only one in vivo study
that has investigated this issue (secondary outcome). No dif-
ference regarding colistin-resistance development could be
seen when comparing colistin vs. colistin and rifampicin,
since no development of colistin-resistance could be detected
in any patient [20]. While our study and many in vitro studies
[9, 10, 16–18] indicate a very high risk of development of
Fig. 1 MIC for rifampicin and colistin after overnight incubation on
MHA. a Colistin-dependent growth—colonies growing only along the
colistin Etest strip. bColistin-resistant subpopulation withMIC for rifam-
picin < 0.002 mg/L
Table 3 Etest MIC of main population and colistin-resistant subpopulations of isolates AB1-AB5
Isolate MIC (mg/L) of main population/colistin-resistant subpopulation
Colistin Rifampicin Vancomycin Linezolid Meropenem Ciprofloxacin Tigecycline Tobramycin
AB1 0.125/128 8/<0.002 >256/0.125 >256/32 >32/0.064–0.25 >32/15– > 32 4/0.5 12/0.5–2
AB2 0.125/12–128 8/<0.002 >256/0.25–1 >256/32–128 >32/0.125–0.5 >32/≥32 4/0.5–1 2/0.5–2
AB3 0.125/– >32/– >256/– >256/– >32/– >32/– 2/– >256/–
AB4 0.125/>256 8/<0.002 >256/2 >256/32 4/0.064 >32/>32 4/1 2/1
AB5 0.125/16–32 4/<0.002 >256/0.125 >256/32 1/0.016 >32/0.032 2/0.064 4/0.064
For AB3 only Etest MIC of main population is presented, since no colistin-resistant subpopulations were detected in this isolate
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colistin-resistance with colistin alone, in vivo studies show
conflicting data [19, 20, 26]. This discrepancy in vivo could
be due to different length of follow up [20, 26], the wide use of
concomitant antibiotics in vivo [20], colistin dosage [20], re-
duced ability for the colistin-resistant organisms to survive
and replicate in vivo [27] or overestimation of the MPC
in vitro [7]. We believe that the MPC of colistin for
A. baumannii is overestimated in vitro due to the inoculum
effect for colistin [28]. No colistin-susceptible cells could be
detected on plates containing ≥ 0.5 mg/L colistin when using
an inoculum of 105 CFU, but up to 32 mg/L with 109 CFU.
No colistin-resistant subpopulations were detected in AB3
and the MPC of colistin alone was also 1–2 dilutions steps
lower for this isolate. TheMPC of colistin was not affected for
AB3 when rifampicin was added. This was expected due to
lack of colistin-resistant subpopulations and the high-grade
rifampicin resistance (MIC > 16 mg/L) displayed by AB3.
High-grade rifampicin resistance is mediated by rpoB-muta-
tions. No additive or synergistic effect is expected for the
colistin-rifampicin combination against isolates carrying this
mutation [25]. To our knowledge no correlation has been
found between rpoB-mutation and lack of colistin-resistant
subpopulations. We therefore believe that the combination of
findings in AB3 were a mere coincidence.
We did not detect any colistin-resistant cells with rifampicin
resistance, but development of resistance due to rpoB mutations
is always a concern when using rifampicin. This mutation can
occur spontaneously or upon rifampicin exposure and colistin-
susceptible A. baumannii, like AB3, readily acquire it [20].
Compared to the main populations, colistin-resistant subpopula-
tions exist in substantially lower numbers [8, 19] and are signif-
icantly more susceptible to rifampicin [11]. It is therefore less
likely that the colistin-resistant subpopulation would mutate in
the rpoB gene spontaneously or upon rifampicin exposure com-
pared to the colistin-susceptible main population.
Colistin susceptibility testing is problematic and
disconcordant results for different susceptibility testing methods
are a well-known problem [29–32]. The categorical agreement
was 100 % for Etest, agar and broth dilution in our study. Only
Etest was used for colonies isolated in the MPC-study to differ-
entiate between colistin susceptible and resistant cells. Thismeth-
od was chosen for practical reasons and because very good per-
formance has been demonstrated with Etest for colistin [29, 30].
However, a risk of Etest falsely classifying isolates as colistin
susceptible has been demonstrated. We had no Etest results in
the range (0.5–2.0mg/L) for which the absolutemajority of these
erroneous results have been demonstrated [31, 32]. We therefore
assess that the likelihood for false susceptible results in our study
is low.
One interesting finding in our study was subpopulations
that exhibited a colistin-dependent growth pattern. This phe-
nomenon has previously been described for colistin and
A. baumannii. The authors suggest that one possible
mechanism for colistin-dependent growth may be a mutation
of lipid A, which results in a defective cell membrane and
osmotic trauma in the absence of colistin [33]. The clinical
importance of these subpopulations is yet to be determined.
In conclusion, our results indicate a risk of selective growth
of colistin-resistant subpopulations with colistin monotherapy
against A. baumannii and that combining colistin with rifam-
picin could be a way to prevent this occurrence.
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